PetVivo Holdings Bets on AI in Upbeat Earnings Call

Petvivo Holdings Inc ((PETV)) has held its Q3 earnings call. Read on for the main highlights of the call.

PetVivo Holdings used its latest earnings call to deliver a strikingly upbeat strategic story despite persistent financial strain. Management showcased new partnerships, an emerging high-margin SaaS model, and a dramatically cleaner balance sheet, arguing these moves outweigh flat revenues and ongoing losses. Investors are now watching whether the company can convert early traction in AI and new products into sustainable growth.

AI Deal Anchors Launch of High-Margin PetVivo AI

PetVivo signed an exclusive 10-year white-label license with Digital Landia for AgenticPet AI and simultaneously launched PetVivo AI as a B2B SaaS platform. Beta tests suggest the system can cut veterinary customer acquisition costs by 50%–90%, reducing typical spend of $80–$400 per client to under $43 and potentially generating recurring revenue at projected 80%–90% gross margins with minimal capital needs.

Early Consumer Beta Validates Demand for AgenticPet

Digital Landia’s public B2C beta for AgenticPet acquired 1,000 active users in less than 72 hours, which management framed as proof of strong consumer interest in AI-driven pet health tools. That rapid adoption is seen as a key validator for the underlying technology and strengthens the commercial rationale for PetVivo AI’s B2B subscription model for veterinary practices.

New Distribution Deals Expand Spryng and PrecisePRP Reach

The company announced a series of commercial partnerships designed to scale product penetration in both domestic and international markets. Veterinary Growth Partners will actively promote Spryng and PrecisePRP to more than 7,300 member clinics, while Nupsala Group has begun distributing in the U.K. and Eq Especialidades is set to open the Mexican market, with initial product shipments already underway.

Health Canada Recognition Opens Canadian Market

Spryng with OsteoCushion technology was formally acknowledged by Health Canada as a veterinary medical device, a key regulatory milestone for the product. This recognition supports a planned commercial launch in Canada targeted for early third quarter of calendar 2026 and positions the company to tap another sizeable international opportunity in companion animal orthopedics.

R&D Pipeline Advances with PiezoBioMembrane Program

Management highlighted progress in its PiezoBioMembrane program, saying Stage A and B work has confirmed basic material compatibility, piezoelectric activity, scalable production, and early animal safety. Stage C, expected to start in the second quarter of 2026, aims to establish definitive animal safety and efficacy and could eventually support a human regulatory pathway, while a canine elbow pilot study is being prepared for publication.

PrecisePRP Commercialization Gathers Momentum

The company is ramping up commercialization of PrecisePRP, an allogenic PRP product licensed exclusively from VetStem, and reported positive veterinarian feedback on ease of use in practice. PetVivo is leaning on major industry conferences and targeted outreach to accelerate adoption, positioning PrecisePRP as a key revenue driver alongside Spryng in its biologics portfolio.

Liabilities Slashed as Balance Sheet De-Risks

PetVivo reported a sharp improvement in its capital structure, with total liabilities reduced to $1.0 million at December 31 from $5.1 million at March 31, an approximate 81% decline. The reduction mainly reflects conversions of convertible notes and the extinguishment of derivative liabilities, which lowers financial overhang and increases flexibility for future financing.

Revenue Holds Steady as Working Capital Improves

For the nine-month period, revenue came in at $887,000, down only 2% year over year despite a shift in product mix and changing promotional strategies. The company ended the period with current assets of $1.4 million, current liabilities of $980,000 and working capital of $395,000, and it has since added about $477,500 from warrant exercises and equity sales.

Spryng Sales Slip as Portfolio Mix Shifts to PrecisePRP

Spryng generated $400,800 in nine-month sales, while PrecisePRP slightly led the portfolio with $486,000, reflecting evolving clinician preferences. Management said Spryng’s year-over-year decline was tied to the lack of last year’s promotions and some practices choosing to use PrecisePRP alone rather than pairing it with Spryng in treatment protocols.

Gross Margin Compresses on Lower-Margin Product Mix

Gross profit for the nine months reached $551,500, representing a 62.2% margin versus a notably higher margin in the prior period, as the mix shifted toward lower-margin PrecisePRP. Executives acknowledged the pressure on gross margin and indicated they are exploring ways to improve PrecisePRP economics, even as they look to offset this with the higher-margin AI SaaS business over time.

Operating Losses Persist and Net Loss Widens

Operating expenses were $6.7 million, a slight 2% decline year over year, yet operating loss edged up to $6.1 million as revenue and margin softness weighed on results. Net loss widened to $7.5 million, or $0.27 per share, compared with $6.0 million previously, driven partly by non-cash items including unrealized derivative losses, asset disposal charges, debt discount amortization, and interest on convertible notes.

Cash Burn Highlights Ongoing Funding Requirements

Net cash used in operating activities for the nine months was $5.3 million, underscoring a meaningful cash burn relative to current asset levels. With working capital of just $395,000 and only $1.4 million in current assets, management was candid that continued access to financing will be critical to support commercialization, AI rollout, and R&D through the next stages.

AI Revenue Timing Adds Near-Term Uncertainty

While enthusiasm around PetVivo AI is high, the company cautioned that revenue associated with Digital Landia-related activities will not be recognized until the next fiscal quarter after April 1. That timing lag means investors should not expect an immediate AI-driven revenue uplift, and the pace of subscription uptake will be a key variable for near-term financial performance.

Lack of Formal Guidance and Listing Challenges Weigh on Visibility

Management declined to reaffirm earlier revenue estimates for the current year and did not provide new quantitative guidance for the core pet-health business, limiting visibility on sales and earnings trajectories. At the same time, plans to uplist have shifted focus to the NYSE American, but leadership warned that current stock levels and a weak life-science microcap environment could delay those ambitions.

Outlook Hinges on AI Monetization and Balance Sheet Gains

Looking ahead, PetVivo expects PetVivo AI to begin contributing revenue in the next fiscal year, with monetization building around mid-year as a monthly recurring SaaS stream with projected high-80s to 90% gross margins and modest capital needs. Management is framing the path forward around AI-driven growth, expanding distribution for Spryng and PrecisePRP, and the significantly reduced $1.0 million liability base, even as it refrains from issuing specific revenue or earnings targets.

PetVivo’s earnings call painted a picture of a small company in transition, moving from a pure-product model toward a hybrid of devices, biologics, and high-margin AI software. Strategic partnerships, international expansion, and a lighter balance sheet support a positive long-term narrative, but investors will need to monitor cash burn, execution on AI subscriptions, and any progress toward uplisting as the next catalysts.